Pharma Journalist

Adenosine-Pathway Targeted Cancer Immunotherapy Summit
2022-05-10 - 2022-05-12 | Omni Parker House, 60 School St, Boston, MA, 02108, United States
Adenosine-pathway therapies have produced a plethora of promising clinical trial data that is being met with refreshed excitement, enthusiasm, and R&D investment for adenosine-pathway targets.
With reinvigorated confidence in the field, join fellow industry and academic thought leaders at the inaugural Adenosine-Pathway Targeted Cancer Immunotherapy Summit. This is the only comprehensive forum dedicated to optimizing efficacy of adenosine-pathway targeted drugs, overcoming challenges of resistance and immunosuppression and supercharging therapeutics to patients in need.
From analyzing the latest developments in understanding adenosine signaling in the TME, to rationalizing drug combinations that enhance patient responses, and exploring tools that quantify adenosine to select patients, this is the one-stop-shop event for all things adenosine-pathway.
Harness cutting-edge insights across 3 days of exclusive content from industry heavyweights including Astrazeneca, Takeda, Corvus Pharmaceuticals, iTeos Pharmaceuticals, Domain Therapeutics and more. Leave this definitive conference equipped with novel ideas, actionable lessons learned and new connections enabling you to progress your adenosine-pathway targeted cancer immunotherapies to the clinic.
To know more visit: https://ter.li/q8tgbz

LEAP HR: Life Sciences West 2022
2022-05-09 - 2022-05-11 | Marriott La Jolla, 4240 La Jolla Village Dr, La Jolla, CA, 92037, United States
LEAP HR: Life Sciences West is your best opportunity to hear how scaling life sciences organizations are implementing the experimental people strategies required to drive innovation and growth whilst operating in a tight talent market.
Step inside 30+ case studies of the radical, future-focused HR thinking that will empower you to transform your impact and turbocharge scale and innovation in biotech, pharma and medical devices organizations.
Gain access to the HR innovation that is truly making a difference to employees, patients and customers – and leave with a brand-new playbook for the people function to thrive in the fast-paced operating environments of life sciences organizations on the West Coast and surrounding areas.
With a world-class speaker faculty from leading life sciences organizations such as: Atara Biotherapeutics, Gilead Sciences, BridgeBio, Assembly Biosciences, Revolution Medicines, 10X Genomics and many more.
Whether your business is rapidly growing, undergoing serious transition or quickly evolving, LEAP HR: Life Sciences West is your opportunity to plug into a ready-made network of peers who have already solved the talent challenges you’re facing in a candidate-led talent market on the tech-hub West Coast and surrounding areas.
To know more visit: https://bit.ly/3h3w3Nt

SMi’s 6th Annual Highly Potent Active Pharmaceutical Ingredients
2022-05-09 - 2022-05-10 | Copthorne Tara Hotel, Scarsdale Place, Kensington, London, W8 5SY, United Kingdom
SMi’s 6th Annual Highly Potent Active Pharmaceutical Ingredients
Conference: 9 – 10 May 2022
London, UK
Website: www.highlypotentapi.com/WLPJ
Chaired by Justin Mason-Home, Owner, Director, HPAPI Project Services Limited
Ensuring Risk-Based, Safety-Driven, High-Quality Operation
SMi is proud to present its 6th Annual Highly Potent Active Pharmaceutical Ingredients, taking place on the 9 – 10 May 2022.
The Global High Potency API/HPAPI Market is projected to reach 37 billion USD by 2027, growing at an ever-increasing CAGR of 8.43%. The expanding production of high potency APIs, along with the increase in associated toxicities, are driving requirements for more effective containment solutions and much-needed guidelines to ensure worker safety.
SMi Group are delighted to announce the 6th Annual Highly Potent Active Pharmaceutical Ingredients Conference will be taking place on 9th – 10th May 2022 in London, UK. The conference will encompass the critical topics including risk assessment, occupational toxicology, engineering controls for containment, facility design, and the impact of pharmaceutical manufacture on the environment.
Benefits of Attending the HPAPI Conference:

Dissect comprehensive hazard assessment and occupational exposure limit determination
Evaluate the increasing trend toward more potent therapies and the consequences of the changing face of pharma
Assess engineering containment controls, from isolators and barriers to fully automated lines
Explore the employment of cleaning validation, organisational controls, and facility as key measure to tackle cross contamination

This two-day conference offers you peer-to-peer networking with industry experts including heads and directors of EHS, Occupational Hygiene, Quality Assurance and more. Expand your community and explore the latest developments in the industry at this two-day event, including key regulatory updates, and leading case studies from leading pharmaceutical and biotechnology companies.
Early Birds:

Register by 31st January to save £400
Register by 28th February to save £200
Register by 31st March to save £100

Event Hashtag: #SMiHPAPi

SMi’s 22nd Annual Pain Therapeutics Conference
2022-05-04 - 2022-05-05 | Copthorne Tara Hotel, Scarsdale Place, Kensington, London, W8 5SY, United Kingdom
SMi’s 22nd Annual Pain Therapeutics Conference
Conference 4 – 5 May 2022
Workshop: 6 May 2022
London, UK
http://www.pain-therapeutics.co.uk/PJwl
Sponsored by: CHDR
Conference Chairman: Richard Malamut, Chief Medical Officer, Collegium Pharmaceutical, Inc
Novel Compounds and Treatments for Pain: Opioids and the Alternatives
SMi’s 22nd Pain Therapeutics Conference will cover the leading advances in pain therapeutics, exploring late development clinical trials, novel treatments for chronic conditions, technology collaboration treatments, using VR and Medical Devices that carry out non-invasive nerve stimulation. Industry leaders will uncover the latest advancements in the field, highlighting the use of opioids and the future for cannabinoids within the pain therapeutics field. Furthermore, policy experts will provide an essential regulatory perspective for this year’s agenda, providing an exciting and comprehensive insight into the pain therapeutics market.
The global Postoperative Pain Therapeutics Market was valued at USD 11.26 Million in 2018 and is projected to reach USD 15.87 Million by 2026, growing at a CAGR of 4.40 % from 2019 to 2026.
The pain industry was affected by Covid-19, with many individuals suffering with pain conditions, unable to get help or treatment. Therefore, there has been a push to ensure that new and more effective treatments will be made available to patients. There is also still a need to move away from opioid based pain treatment.
Join Europe’s leading Pain Therapeutics Conference in May 2022 to explore new case studies and regulatory perspectives as well as uncover challenges and successes of both pre-clinical and clinical Pain R&D development to equip you with the necessary knowledge to advance R&D in the pain therapeutics industry.
Event hashtag: #SMiPain
Key Reasons to Attend the Conference:

Discover the new treatments available for those with pain diseases, such as migraine, atopic dermatitis and muscle spasms
Develop your knowledge of analgesics for the treatment of pain
Discuss the new alternative treatments for pain and the use of opioids within the field
Network with industry professionals and discuss recent advances in the industry

View the full agenda: http://www.pain-therapeutics.co.uk/PJwl
Who Should Attend?
Chief Executive Officer, Chief Scientific Officers, Chief Medical Officers, Managing Directors, CEO, Head of Department, Principal Research Scientists, Clinical lead, Clinical Operations in the following fields:

Pain and Migraine
Inflammation
Chronic Pain
Neuropathic Pain
Analgesic pre-clinical development
Anaesthesia and Pain Management
CNS clinical trials
Ion Channel Pharmacology
Pharmacology Intelligence
Translational science
Drug development
Exploratory development

Workshop: Friday 6 May 2022
Molecular and Cellular Pathophysiology of Pain Resolution
Workshop Leaders:
Luda Diatchenko, Canada Research Chair in Human Pain Genetics, Department of Anesthesia, Faculty of Medicine, McGill University
Julio Reinecke, Chief Scientific Officer and Co-Founder, Orthogen
Peter Wehling, CEO and Founder, Orthogen
Ru-Rong Ji, Professor in Anesthesiology, Distinguished Professor of Anesthesiology, Professor in Neurobiology, Professor in Cell Biology, School of Medicine, Duke Neurobiology

SMi’s 5th Annual Pharmaceutical Microbiology East Coast Conference
2022-04-27 - 2022-04-28 | Sheraton Boston Hotel, 39 Dalton Street, Boston, MA, 02199, United States
SMi’s 5th Annual Pharmaceutical Microbiology East Coast Conference
Conference: 27 – 28 April 2022
Workshops: 29 April 2022
Boston, MA, USA
http://www.microbiologyeastcoast.com/PJwl
Sponsored by: Bioscience International, Associates of Cape Cod and Microbiologics
Chaired by: Jim Polarine, Senior Technical Service Manager, Head of Microbiology & Sterile Technology, STERIS Corporation
Harnessing existing methods and novel tools in microbial control to assure continuity in product quality and patient safety
SMi’s 5th Annual Pharmaceutical Microbiology East Coast Conference is taking place in Boston on April 27-28, 2022, with interactive workshops on April 26, 2022.
Microbiology remains an essential tool in reducing microbial growth in the manufacture of pharmaceuticals, to detect and eliminate microorganisms that would pose a risk to patients and jeopardise product batches.
Ensuring the sterility of the finished product continues to be one of the most critical aspects of drug development, however an array of factors are also sustaining new growth and transformation in this field. The regulatory landscape is changing, firstly with the preparation of Annex 1, in addition to increasing requirements pertaining to data integrity. Light is being shed on recent product recalls for mould contamination, and infection outbreaks serve as a reminder to pay more attention to these overlooked organisms, as well as considerations towards container closure integrity testing which is being increasingly deployed to block microbe movement.
On top of this, the developing integration of automation and robotics into the manufacturing pipeline, as well as the increased need for more rapid microbiology methods brought about in part by the surge in ATMPs, are all highlighting the necessity of the field in Pharma.
This industry is ever expanding, join leading experts in 2022 to discuss and analyse the latest advances and challenges surrounding Pharmaceutical Microbiology. Network with industry professionals, discuss revisions in regulatory and guidance documents, and gain a deeper insight into this corner of the field.
Event Hashtag: #SMiPharmaMicroEC
Key Highlights for 2022:

Review implementation guidance and validation for efficient disinfectant efficacy programs
Uncover principles in best-practice and the benefits of a robust contamination control strategy
Address fungal mould contamination and risk-based tools to tackle spore spreading
Delve into the sterility assurance assessment and holistic closure integrity testing
Explore the impact of the ongoing pandemic and the changing face of the pharma industry
Understand new unique case studies, from contamination control as it relates to microbiome products, to risk-based assessments of traditional microbiological tests
2 Interactive Pre-Conference Workshops on April 26, 2022

Interactive Workshops:
Workshop A: Risk Assessment and Cleaning Validation
Workshop Leader: Fred Ohsiek, SME, Cleaning Validation, North America
Workshop B: USP Microbiology 2022 – Keeping Up with Standards
Workshop Leader: Donald Singer, Chair, General Chapters – Microbiology Expert Committee, US Pharmacopeia and Ecolab Life Sciences
View the full agenda: http://www.microbiologyeastcoast.com
WHO SHOULD ATTEND?
Senior Microbiologist, Lead Scientist, Laboratory Manager, QA Specialist, Drug Substance External Manufacturer, QC Scientists, Heads of Quality, Business Development Manager, Pharmaceutical Microbiology Consultant, Higher Pharmacopoeia Scientist, Analytical Standards Specialist

6th R&D Sourcing & Procurement Summit in Pharma
2022-04-26 - 2022-04-28 | The Bostonian Boston, 26 NORTH STREET, BOSTON, MA, 02109, United States
We are excited for the 6th Advanced R&D Procurement & Sourcing in Pharma Summit returning to Boston in April, reuniting senior leaders to share their stories and lessons learned, and how they implement strategic sourcing to optimize spending and mitigate risks.
As the one and only community dedicated to 100+ R&D procurement, category management, and sourcing professionals, this is your must-attend conference in 2022 to benchmark your SOPs against your peers and stay at the forefront of technology to streamline your procurement processes. Leave this meeting with practical tips to drive scientific innovations with sustainability, optimized spend and strengthened vendor relationships!
Your Unmissable Spotlight Case Studies In 2022:

Establish robust external supplier relationship models to advance your pipeline development with Betrand Rosier, Global Procurement Head, Sanofi
Rebrand procurement to be your scientists’ best business partner with Gerard Cardillo, Vice President, Global Procurement
Explore lessons learned from COVID including strategic investing with Sean Cumbie, Vice President, Global Sourcing & Procurement, NOVAVAX
Develop sourcing & procurement strategies at lightspeed with James Tornos, Vice President, Sourcing & Enterprise Services – Research, Development and Medical Procurement, Pfizer
Deep-dive into driving D&I initiatives, both within companies and through supplier diversity initiatives in an exclusive, interactive workshop led by Manuele Burdese, Senior Director, Head of Business Insights & Analytics Strategic Sourcing & Procurement, Bristol Myers Squibb, Tom Thattacherry, Head, Supplier Diversity, Genentech

To find out how you and your team can get involved download your free event guide or get in touch.

5th Neoantigen Summit Europe
2022-04-26 - 2022-04-28 | Leonardo Royal Amsterdam, Paul van Vlissingenstraat 24, Amsterdam, 1096 BK, Netherlands
The 5th Neoantigen Summit Europe, the definitive industry meeting for uncovering the full potential of neoantigens in creating individualised neoantigen vaccines is returning in person!
From understanding the latest clinical insights to reviewing vaccines post-COVID, our 35+ expert speakers and 3-day agenda developed alongside #Vaccibody, #Gritstonebio, #Targovax, #Vaximm, #Immunetune and #OdimmaTherapeutics will help you advance your pipeline to successfully weaponise neoantigens for anti-tumour treatment.
Join 100+ colleagues and take on the next frontier in neoantigen identification and vaccine manufacturing.
Key speakers include: Agnete Fredriksen, Chief Innovation & Strategy Officer, Nykode Therapeutics | Barbara Loesch, Head of Technology and Innovation, Medigene |Jessica Matta, Co-Founder & Chief Executive Officer & Chief Scientific Officer, Odimma therapeutics | Andrew Allen, CEO, Gritstone bio | Peter Sondermann, CEO, Tacalyx GmbH |Sijme Zeilemaker, Chief Executive Officer, Immunetune
Find out more in the event guide here: https://ter.li/gulg78
Visit the official event website here: https://ter.li/s89k61

Reuters Events: Digital Health 2022
2022-04-26 - 2022-04-27 | Mission Bay Resort, San Diego, California
Join the world’s leading forum for advancing the delivery of digital care
Digital Health’s deployment has been as fast as it has wide. Overnight it has become the central focus for hospitals, clinics and health plans across the nation. The result? Workflows are more complicated than ever. We’re failing on patient engagement. And we still lack a clearly defined digital care payment infrastructure.
Now is the moment to tackle inefficiencies in our use of digital health or risk sub-optimal becoming the new norm. We must not squander the biggest opportunity for the industry’s advancement in half a century.
That’s why we’ve created Reuters Events Digital Health – the place where the standard is set by 300+ executives for the delivery of quality virtual, predictive, affordable and equitable care. Our world-leading forum is where leaders of health systems, payers, policy makers, pharma and health tech converge to realize the transformative potential of technology in healthcare.

2nd Ligase Targeting Drug Development Summit
2022-04-26 - 2022-04-28 | Online, EDT
Whilst the exploiting of this therapeutic modality surges through biopharma and academia, it is essential that we unlock the fundamental challenges within this industry, as this remains a key factor determining success of degraders in the clinic.

The 2nd Ligase Targeting Drug Development Summit returns to Boston in April again uniting industry frontiers and leading minds, as together we discuss, update, and learn how to successfully hijack ligases for therapeutic application, and uncover a critical piece of the puzzle in realizing the full potential of this therapeutic approach.
Filling the gap of an industry-led ubiquitin discussion, we again provide an unrivalled forum to unite leading biopharmaceutical giants, alongside key academics, to share unseen data, collaborative efforts and discuss next steps to successfully select, validate and translate E3’s into a viable therapy.
Join us in Boston to expand your understanding of the ever-broadening ligases field and the fast-improving chemical biology tools to seize the therapeutic value of Ubiquitin E3 ligases and differentiate your pipelines.
To Know more visit: https://ter.li/rm8y7d

3rd Supply Chain and Logistics for Cell Therapies Summit
2022-04-25 - 2022-04-27 | Crowne Plaza Boston – Woburn, an IHG Hotel, 15 Middlesex Canal Park Rd, Woburn, MA, 01801, United States
Keen to unite with your #celltherapy supply chain community and gain actionable insights for streamlining logistics, implementing digital platforms and optimizing patient operations to establish a reliable global delivery of cell therapies?
Then look no further! The 3rd Supply Chain & Logistics for Cell Therapies Summit is back and taking place in-person for the first time this 25-27 April 2022!
View the full 3-day agenda here: https://ter.li/yp10r2
2022 Agenda Overview:
With exclusive presentations and interactive talks on key industry challenges, gain valuable takeaways from leaders in the field from GlaxoSmithKline, Legend Biotech, Iovance, Gamida Cell, and more. Discuss standardization, review digital system implementation, prepare for upscaling and optimize cryopreservation in person with like-minded supply chain professionals all to maximize efficiency and create a patient-centric end-to-end system.
Download the full event guide to learn more about our speakers, agenda topics, and face-to-face networking opportunities. https://ter.li/yp10r2

Novel Format Conjugates Summit
2022-04-25 - 2022-04-27 | Omni Parker House, 60 School St, Boston, MA, 02108, United States
The inaugural Novel Format Conjugates Summit exclusively focuses on the common challenges across early research and development of next generation Non-Traditional ‘ADCs’, or alternative format conjugates approaches for oncology and beyond. This meeting delves into the different technologies of these novel-format conjugates, exploring how conjugation chemistry is affected for different kinds of therapeutic modalities, and the impact an alternative format ADC has on targeting.
As we look to the future of drug development of novel conjugates, you will get the chance to hear the cutting-edge science accelerating the development of Bispecific ADCs, Radio-conjugates, ISACs, SMDCs, Probody conjugates, Liposomal drug conjugates, Oligonucleotide conjugates and many more.
Engage in cross-industry discussions and presentations from over 20 expert speakers across 3 unmissable days and equip yourself with the tools to develop novel format ADCs with an improved therapeutic potential so we can bring more drugs to patients of unmet needs.
To know more visit: https://ter.li/0811lm

2nd Chronic HBV Drug Development Summit
2022-04-25 - 2022-04-27 | Wyndham Boston Beacon Hill, 5 Blossom St, Boston, MA, 02114, United States
With a tight focus on late translational to phase II clinical progress, the 2nd Chronic HBV Drug Development Summit returns in person as the definitive industry forum to advance combination therapy and achieve functional cure in hepatitis B virus.
Dedicated to advancing direct antiviral and immunotherapy pipelines in combination therapy paradigms, this industry-orientated forum is timely positioned after EASL to reset standards after the latest readouts.
From transformative advances in establishing synergistic combination regimens, to navigating clinical endpoints and stopping points, and illuminating the role of immunotherapy to attain durable functional cure, don’t miss your chance to join the conversation.
Harness actionable insights across 3 days of exclusive content from 20+ scientific experts including Gilead Sciences, Vir Biotechnology, VBI Vaccines, Altimmune, Drug Farm, Replicor and many more to guide your strategic decisions and drive clinical progress.
Join us in Boston to forge successful industry collaborations in combination therapy for chronic HBV.
To know more visit: https://ter.li/o1utyk

SMi’s 9th Annual Conference Pre-Filled Syringes East Coast
2022-04-25 - 2022-04-26 | Sheraton Boston Hotel, 39 Dalton Street, Boston, MA, 02199, United States
SMi’s 9th Annual Conference
Pre-Filled Syringes East Coast
Main Conference: April 25 – 26, 2022 | Workshops: April 27, 2022
Sheraton Boston Hotel, Boston, MA, USA
www.pfsamericas.com/pharmajournalistwl
Sponsors are: SCHOTT, ZEON
Exhibitors: Owen Mumford Pharmaceutical Services, PHC Corporation, POLYPLASTICS- TOPAS, Weiss-Aug Group
Device innovations, connected delivery and regulatory guidance for advanced parenteral systems
The global pre-filled syringes market was valued at $1139.6 million in 2020 and with the rapid growth of the industry, is expected to grow at a CAGR of 8.95% up to 2027. With that in mind, the 9th annual Pre-Filled Syringes East Coast conference will bring together leading industry experts representing big pharma and device developers to discuss the key drivers accelerating the expansion of the industry.
The past year has seen significant developments in the injectables landscape with the rapid introduction and development of vaccines in response to the pandemic, updates in regulations including the EU MDR and FDA guidance on bridging studies, and increasing industry acceptance of connectivity to aid the user experience. As part of SMi’s leading injectable series, the 2022 conference will provide an exclusive insight into the latest developing technologies for device design, advances in parenteral device platforms and development, insights into growing integration of digital health and deep dives into recent case studies on novel delivery systems.
This two-day agenda offers you peer-to-peer networking with Global Product Managers, Senior PFS Engineers, Device Testing Managers, Heads of Late-Stage PFS Development and many more.
Visit the website at: www.pfsamericas.com/pharmajournalistwl
Chair for 2022:
Gretchen Vandal, Sr. Director, Head of Global Regulatory Affairs – Devices and Combination Products, Takeda
Guest FDA Speaker:

John Barr Weiner, Associate Director for Policy and Product Classification Office, Office of Combination Products FDA

Featured 2022 Speakers Include:

Joyce Zhao, Associate Director, Combination Product, Takeda
Suzette Roan, Associate VP and Head of Global Device Regulatory Affairs, Sanofi US
Christine lynn lanning, Distinguished Scientist, Device Area Leader, Merck
Heather l. Guerin, Associate Director, Regulatory Affairs – CMC, JanssenTieming Ruan, Senior Director of Device Development, Alexion Pharmaceuticals
John Schalago, Executive Director, Senior Global Program Director Regulatory Affairs, Novartis
Gretchen Piwinski, Manager, Combination Product Laboratories, Regeneron
Michael Song, Associate Director, Takeda
Deep S Bhattacharya, Senior Scientist, Drug Product Development and Design, Pfizer

BENEFITS OF ATTENDING:

Explore the latest developments in innovative technologies for device design accelerating the path to self-administration
Assess the evolving regulatory landscape for pre-filled syringes and discuss approaches to work with regulators as guidance is updated
Engage in panel discussions with industry leaders to navigate the accelerating digital health landscape for combination products and drug delivery systems
Understand the landscape of delivery for novel drug products and key considerations to overcome challenges in CCI

View the full agenda and speaker line-up online: www.pfsamericas.com/pharmajournalistwl
Who should Attend:

Drug-delivery developers
Medical Device Engineers
Primary Packaging material designers
Secondary packagers
Smart device developers
Training device developers
Device-safety solution providers
Drug developers

EARLY-BIRD RATES:

BOOK BY 17th DECEMBER AND SAVE $400
BOOK BY 31st JANUARY AND SAVE $200
BOOK BY 28TH FEBRUARY AND SAVE $100

Registrations can be made on the event website at: www.pfsamericas.com/pharmajournalistwl

CPhI & P-MEC China Virtual Expo Connect
2022-04-21 - 2022-06-30 | Online
This year CPhI & P-MEC China returns as a SMART event, combining 2 months of online event with a 3-day in-person event to help you connect for an extended period.

“Virtual Expo Connect”, to be held from 21st April – 30th June 2022, is the digital extension of the physical CPhI & P-MEC China event that offers an online alternative for global pharma professionals.
Powered by PharmaSources.com, Virtual Expo Connect builds the online platform adding valued services and infinite opportunities to connect, learn, trade and grow.
To know more visit: https://www.pharmasources.com/vec2022

2nd Gene Therapy Medical Affairs Summit
2022-04-19 - 2022-04-21 | Westin Boston Seaport Hotel, 425 Summer St, Boston, MA, 02210, United States
Transforming Traditional Medical Affairs
Optimize Medical Affairs Proactive Engagements and Education Initiatives to Successfully Launch the Next Generation of Gene Therapy Products
The 2nd Annual Gene Therapy Medical Affairs Summit is dedicated to exploring the pivotal internal and external role Medical Affairs plays in delivering gene therapies to patients. This is your opportunity to take inspiration from Medical Affairs leaders of the gene therapy world and learn how traditional Medical Affairs approaches are being transformed to meet the unique challenges associated with gene therapy drug development.
Gain actionable insights from first-to-market pioneers, who will share how to engage effectively with internal clinical, commercial and regulatory teams as well as external HCPs, regulators and patient advocates to create a cohesive and streamlined launch strategy for complex, high priced Gene Therapy products.
The summit will provide a dedicated platform that discusses the role and value of Medical Affairs across each of the phases of the gene therapy development cycle. We will delve into the unique challenges encountered when working with gene therapies, from adapting to the clinical realities of the rare disease space, to handling long-term follow up and post-launch regulatory scrutiny, equipping you with the insights required to launch gene therapy products more efficiently and effectively than ever before.
To know more visit: https://ter.li/xciowp

LNP Formulation & Process Development Summit
2022-04-12 - 2022-04-14 | Boston Park Plaza, 50 Park Plaza, Boston, MA, 02116, United States
Embrace Technology Innovations to Optimize LNP Formulation, Alternative LNP Raw Materials, Process Control to Achieve Seamless Scale-Up, Compliance & Cost Effectiveness
The inaugural LNP Formulation & Process Development Summit is the industry’s first forum dedicated to bringing together drug developers within the LNP field to share the latest scientific breakthroughs on formulation and process development. Across 3 days, you will address challenges and seek solutions to help you optimize your formulation to enhance stability, efficacy, and better characterization for drug product quality. This is your chance to explore the use of alternative polymer lipids to maximize scalability and moving towards cGMP manufacturing for pipeline progression.
The global nanopharmaceutical drugs market, catalyzed by the success of Pfizer/BioNTech and Moderna’s mRNA vaccines, is poised to reach US$82.7 billion by 2027. The demand of novel LNP to support the delivery of oligonucleotide and nucleic acid-based therapies is growing at an exponential rate. With the overwhelming possibilities of lipid nanoparticles, there are key questions on formulation, process development and scalability that still need to be answered. There has been no better time to join forces and help accelerate the development of truly remedial LNP therapeutics.
To know more visit: https://ter.li/8hrml3

Purify’22
2022-04-07 | ITC Kohenur,Hyderabad
PURIFY Conclaves are pioneers of dedicated conferences in India that will help stretch possibilities, be it discovery, development or scaleups!
The pharmaceutical industry continues to dwell deeper into the growing possibilities for chromatography purification; the PURIFY conclaves touches upon diverse aspects of chromatography purification.
The attendees at PURIFY get exposed to a myriad of topics that could change the way they work…change the way they purify. New separation techniques and approaches, niche topics, deeper understanding of preparative and process chromatography and allied fields, and upcoming application areas that will provide quality substance to the discerning scientists. So, if you wish to get that additional gram, which is purer, in as less a time, with minimal resources…there will surely be something for you at PURIFY conclaves!
The annually occurring PURIFY Conclave is an initiative by Custage Marketing Solutions LLP, a Mumbai based company.
The PURIFY conclave is attended by analytical and research chemists, scientists with scale-up and process development knowledge, managers, group heads, natural product purification experts, experts from quality and manufacturing, academicians, policy makers, supply chain heads etc. of this pharmaceutical – APIs, peptides, proteins, oligonucleotides, chiral molecules, bio-pharmaceutical, fine chemicals, environmental studies, food and beverage, polymers, biotechnology, cosmetics and fragrance to understand the advancements in chromatography platforms.
The maiden PURIFY’19 edition was a huge hit amongst fellow chromatographers, steered by our esteemed advisory board.
PURIFY’19 was attended by 113 delegates across 19 cities, spread across 51 corporates with 14 speakers and 6 display zones!
So, the purification expert in you will surely get answers to the daily challenges faced for you in your laboratories. And what’s more, the knowledge comes to you from dignitaries who are institutions on their own in chromatography purification and related.
Download Brochure

Wet AMD & DME Drug Development Summit
2022-04-05 - 2022-04-07 | Embassy Suites by Hilton Boston Logan Airport, 207 Porter St., Boston, MA, 02128, United States
Accelerating the Development of Novel Anti-VEGF, VEGF-independent Therapies & Drug Delivery Options To Reduce Clinical Burden, Widen Therapeutic Index & Treatment Options for Non-responders
The second edition of the industry-led Wet AMD & DME Drug Development Summit will give comprehensive insight into the current and emerging angiogenesis-, inflammatory-directed and anti-fibrotic drug development programmes for these three ophthalmic conditions – neovascular age-related macular degeneration (wet AMD), diabetic retinopathy (DR) and diabetic macular edema (DME).
The 2022 Summit will include interactive presentations and panel discussions, covering challenging questions for the whole research community such as:

What are the future directions for anti-VEGF therapy to increase patient response rates, prolong treatment durability and reduce clinical burden?
Where is the clinical success for targeting VEGF-independent pathways in this multifactorial disease?
What interventions beyond anti-VEGF give treatment options for refractory or not optimally treated patients?
How are drug developers using various drug delivery methods – topical, intravitreal, suprachoroidal, port delivery – to expand the therapeutic window?
How has optical coherence tomography (OCT) imaging, including at-home diagnostic testing, and artificial intelligence-enabled programming personalized wet AMD and DME treatment and supported clinical trials?

As the only industry-led forum solely dedicated to finding long-lasting therapeutic interventions for wet AMD and DME, attendees will have the opportunity to review the multiple pathological mechanisms being actively targeted, identify the latest clinical data from anti-VEGF suppression (antibody fragments, delivery systems, bispecific antibodies, gene therapy), combinational approaches, non- VEGF pathways (integrin and TKI’s) and VEGF-independent (such as targeting plasma kallikrein) therapies.
Meet the leading ophthalmology drug developers from big pharma, biotech and academia searching for treatment breakthroughs and actively gathering clinical evidence to demonstrate a favourable benefit/risk ratio for future products to regulators, clinicians and payers.
Join us next April to hear their latest clinical development programs and identify future portfolio strategies for your organisation.
To know more visit: https://ter.li/m98rr7

2nd Gene Therapy for Muscular Disorders Summit
2022-04-04 - 2022-04-07 | Hanson Wade, Hyatt Regency Boston Downtown, 1 Ave de Lafayette, MA, 02111, United States
Mitigating Toxicity & Revolutionizing Muscle Targeting
The 2nd Gene Therapy for Muscular Disorders Summit will be returning as an in-person event to Boston in April 2022, to help gene therapy developers targeting muscular disorders to overcome safety and toxicity
challenges and effectively translate their programs into the clinic.
Highlighting AAV and gene editing challenges for Duchenne’s (DMD), Limb-Girdle (LGMD), Pompe Disease, X-Linked Myotubular Myopathy and other muscular disorders, this industry-focused 4-day event will cover:

Overcoming immunogenicity challenges and mitigate toxicity with high doses
Optimizing vector and promoter choice and design for more efficient delivery tomuscle targets
Defining clinically meaningful muscular endpoints to successfully develop and safely deliver the optimal dose to their muscular targets

Join over 150 fellow industry experts to learn, share and benchmark yourselves against your competitors, and overcome the toxicity and dosage challenges hindering the progress of your gene therapy targeting the muscle.
To know more visit: https://ter.li/tbbaua

7th Innate Killer Summit 2022
2022-03-30 - 2022-04-01 | Sheraton San Diego Hotel & Marina, 1380 Harbor Island Drive, San Diego, CA, 92101, United States
2021 was a game-changing year for the NK cell community. Positive clinical results have forced the field to wake up to the potential of these pioneering approaches.
Supporting the field since its’ infancy, the Innate Killer Summit returns for its 7th year as the leading, industry-defining forum dedicated to advancing the field to achieve clinical success.
Spanning the current drug development landscape, from improving gene editing transduction in discovery to cryopreservation and CMC in scaled manufacturing, this is the definitive meeting to focus on the clinical and scaled phase development of innate cell therapies.
Get your copy of the 2022 agenda here.
Join over 200 experts to characterize and contrast cell sources, supercharge combinations, optimize CMC workflows, examine expansion protocols for high-quality products at scale, and move the field towards persistent, scalable, and cost-effective innate immune cell therapies.
Promising unpublished data, interactive discussion, and engaging networking opportunities join this exclusive summit to forge new collaborations and capitalize on the clinical potential of innate immune cell therapies.

Next Generation Kinase Inhibitors Summit
2022-03-29 - 2022-03-31 | Boston Park Plaza, 50 Park Plaza, Boston, MA, 02116, United States
Celebrating 20 years of FDA approval and high efficacy profiles, kinase inhibitors have changed the face of oncology treatment. However, increasing resistance and safety issues limit the success of existing kinase inhibitor classes.
The inaugural Next Generation Kinase Inhibitors Summit is the only industry-focused meeting dedicated to applying novel kinase biology to drug development and innovating existing programs to produce the next wave of kinase inhibitor drugs which are able to show efficacious and durable clinical response in oncology and beyond.
Boasting 20+ speakers, 1 deep-dive workshop and over 3 days of unrivalled content spanning discovery, R&D and clinical development, this event is a unique opportunity for your team to identify and target the undruggable, elevate drug design for improved target selectivity, overcome the blood brain barrier and rationalize combinations for more durable responses.
Collaborate with 80+ senior drug developers in March to achieve the next generation of these kinase inhibitor therapies with optimized specificity, maximal durability to deliver the best clinical outcomes.
To know more visit: https://kinase-inhibitors-summit.com/

12th World ADC London
2022-03-29 - 2022-04-01 | Novotel London West, 1 Shortlands, Hammersmith, London, W6 8DR, United Kingdom
12th Annual World ADC London
29th March – 1st April 2022
London
The ADC field is going from strength to strength, further catalysed in 2021 by the approvals of Zynlonta and Tivdak respectively, bringing the total number of commercially available ADCs to 11.
Returning in-person in from 29th March – 1st April, be part of the 12th Annual World ADC London and reconnect with 400+ of your peers at the forefront of ADC drug development.
After in-depth research with key opinion leaders within the ADC field, this is your most extensive programme to-date addressing the most pressing challenges facing ADC developers from discovery through to late phase manufacturing.
Take a look at the brand-new agenda here!
The four-streamed, four-day unrivalled programme with 75+ industry-leading speakers will equip you with the insights and connections to nourish your current pipelines of ADCs, discover the next generation of non-traditional ADCs, and confidently define your manufacturing processes.
Register now and join the likes of the likes of Daiichi Sankyo, AstraZeneca, ADC Therapeutics, Seagen and many more to work collaboratively to overcome the distinct challenges ADC drug development holds and maximise the therapeutic window of ADCs.

3rd Annual Gene Therapy for Blood Disorders
2022-03-29 - 2022-03-31 | Boston Logan Airport Hotel, One Hotel Dr, Boston, MA, 02128, United States
In the context of intense scrutiny over the safety and durability of blood disease-targeted gene therapies and a flurry of excitement around novel gene editing technologies, the 3rd Gene Therapy for Blood Disorders Summit will unite the leading large pharma and innovative biotechs to share essential learnings from across this rapidly evolving field, enabling you to progress your pipeline to address the significant unmet need in this field.
Focused specifically on hemophilia, beta-thallasemia and sickle cell-directed gene therapies and gene editing approaches, this event is an invaluable opportunity to learn the realities of durability challenges, understand strategies to guarantee safety at every stage of development and get a head-start in understanding the most promising technologies set to revolutionise the field.
Incorporating insights from translational, clinical and commercial industry experts, as well as leading clinicians actively involved in late-stage trials, this is your opportunity to investigate the realities of managing immunogenicity for systemically administered gene therapies, establishing less cytotoxic conditioning regimens for ex vivo approaches and prepare for the commercial reality of launching a gene therapy and ensuring there is widespread patient adoption.
To know more visit: https://ter.li/u41qa2

STING & TLR-Targeting Therapies
2022-03-22 - 2022-03-24 | Hilton Boston Logan Airport, One Hotel Dr, Boston, MA, 02128, United States
The 3rd STING & TLR-Targeting Therapies Summit is coming at a timely inflection point in this field.
With multiple TLR agonists moving into the clinic, STING agonists exposing new challenges, multiple approvals on the horizon, and more novel targets & combinations currently undergoing exciting pre-clinical validation than ever before, this unique and highly anticipated industry-focused meeting will unite experts in innate immunity to overcome the barriers it faces and accelerate clinical breakthrough.
Returning in-person to the biopharma hub of Boston, 30+ expert speakers will take you through case-study led presentations, juicy panel discussions and live Q&A’s, all tailored to suit your TLR, STING & other PRR targeting needs.
Gain connections and insights to plan how to optimize the development of your innate immune agonists into the clinic and overcome obstacles that may impede the delivery of more selective, better-tolerated medicines to improve survival rates in difficult-to-treat cancers.
To know more visit: https://ter.li/z3s9wq

GPCRs - Targeted Drug Discovery Summit
2022-03-22 - 2022-03-24 | DoubleTree Suites Boston-Cambridge, 400 Soldiers Field Rd, Boston, MA, 02134, United States
The inaugural GPCRs – Targeted Drug Discovery Summit has been established to tap into new drug discovery opportunities in undrugged and orphaned GPCRs by better understanding the complex signaling GPCR pathway, leveraging new structural and genetic data as well as, emerging screening tools and technologies and up and coming modalities.
Discover data driven case studies that showcase the challenges, learnings and takeaways currently being faced by large pharma, biotech and academia who are innovating their discovery and development approaches to drug a wider spectrum of clinically relevant but poorly characterized or undrugged GPCRs across a broad range of therapeutic areas such as oncology, age-related diseases and beyond.
Whether you are looking to harness the power of structural biology tools or emerging technologies, join fellow directors, heads and VPs of drug discovery, structural biology, and pharmacology at the GPCRs – Targeted Drug Discovery Summit – the most comprehensive and dedicated scientific and networking forum for innovative biopharma and research institutes to seize the therapeutic opportunities of GPCRs.
To know more visit: https://ter.li/d9fxmw

SMi Presents the 16th Annual Conference: Parallel Trade 2022
2022-03-21 - 2022-03-22 | Virtual Conference: Online Access Only
SMi’s 16th Annual Conference
Parallel Trade
21-22 March, 2022 | Conference
http://parallel-trade.com/pharmajournalistwl
NAVIGATING THE CHALLENGES AND LEGAL LANDSCAPES OF PARALLEL TRADE
SMi presents its 16th annual Parallel Trade conference on the 21st and the 22nd March 2022. As the only parallel trade conference in Europe, this event provides the perfect platform for industry experts from both sides of the coin to come together and share perspectives on the practice of parallel trade.
The 2022 event will be more significant than ever before due to the transition period follow Brexit now also coming to an end. As such, the UK will no longer be part of the EU free market. This will mean increased medicines prices, reduced access to some specialist drugs and greater risk of supply chain shortages. In a post-Brexit environment, exhaustion of rights will cease to apply to the UK, making import and export a costly business and in a worst-case scenario could effectively kill parallel distribution.
This conference will bring together industry experts to discuss the challenges and drivers of the industry, including the EU regulatory landscape and the impact of the Brexit and the Pandemic together. The conference will also provide global insights on Parallel trade and will reflect on key takeaways for other member states.
Benefits of Attending:

Discover the impact of Covid-19 on Parallel trade as countries begin to release restrictions. How has the sector been influenced?
Engage in discussions on the growth within parallel trade over the past year at the only Parallel Trade specific conference within the EU.
Discuss the impact on UK parallel trade following Brexit, through the eyes of regulators, the pharmaceutical industry and academics
Develop further understanding of the rules and regulation changes over the past 12 months, Parallel Trade, where are we now?

Who Should Attend:
Vice President/ Heads of/General Managers:
• International Trade and Relations
• Supply Chain Development – Brexit
• Brexit Implementation
• Market Access
• Supply Chain Manager
• Parallel trade reporting
• Regulatory Affairs
• IP
• Purchasing
• Policy Patent Operations
• European Affairs
• Supply and Demand
• Attorney
• Distribution
Please visit http://parallel-trade.com/pharmajournalistwl for more information, to download the full agenda, or to register your place. If you would like to speak to someone about the event please contact Alia Malick amalick@smi-online.co.uk or call +44 (0)20 7827 6168.

2nd TPD Europe Summit
2022-03-15 - 2022-03-17 | London, UK
2021 marked a successful year for the protein degradation field with several candidates entering the clinic. As the European centric targeted protein degradation landscape matures and the number of pre-clinical candidates expected to enter clinical development in the next year grows ever more, the 2nd TPD Europe Summit returns, in person, to highlight key challenges and opportunities ahead!
Built with biopharma in mind, join us as we take a deep dive into how European leaders of protein degradation are approaching key translational challenges including optimisation of selectivity, bioavailability and PKPD to ensure the safety, efficacy and potency of their clinical pipelines in 2022 and beyond!
Be at the heart of the discussion by joining 180+ Senior Scientists, Principal Investigators & Heads of Discovery, Pre-Clinical & Translational Development from Europe and around the globe for two dedicated streams of exciting content over three days to capitalise on this emerging therapeutic class.
Key Highlights Not to Miss:

Hear from Kevin Moreau, Assoicate Director PROTAC Safety Science, AstraZeneca as he discusses key PROTAC safety considerations for both oncology and non-oncology indications including how to optimise the safety profile, and what is acceptable for non-oncology targets

Delve into COFFEE (covalent functionalisation followed by E3 electroporation), which tests neo-substrate degradation by chemically modified E3 ligase components. Brought to you by Benika Pinch, Principal Scientist, Novartis, she discusses how to assess the cellular activity of E3 ligase components

Uncover how protein manipulation using peptides can be used to degrade proteins using either the UPS or lysosomal pathways. This exciting approach relocates protein within the cell and modulates their interactions. Hear Max Cynader, CEO & Co-Founder Primary Peptides discuss in detail!

Amine Sadok, Head of Biology at Monte Rosa Therapeutics will be discussing how they have identified a potent and selective NEK7 molecular glue degrader as a novel CRBN neo-substrate

Digital passes available
To know more visit: https://ter.li/j3ytqu

SMi’s 3rd Annual AI in Drug Discovery Conference
2022-03-14 - 2022-03-15 | London, United Kingdom
SMi’s 3rd Annual AI in Drug Discovery Conference
Conference: 14 – 15 March 2022
London, UK
Website: http://www.ai-indrugdiscovery.com/PJwl
Chaired by Darren Green, Director of Computational Chemistry, GSK
Sponsored by: Optibrium
Exploring the Impact of Machine Learning and Artificial Intelligence in Drug Development from Discovery to Healthcare
SMi Group is proud to present its 3rd Annual AI in Drug Discovery Conference, taking place on the 14th and 15th March 2022 in London, UK.
With the recent pandemic highlighting the need for rapid drug discovery, AI has become an area of increased interest. This is driven by the ability to discover drugs through the use of machine and deep learning. The current challenges within the drug discovery industry include the significant time consumption and expenses involved. This conference will discuss the solutions to these problems with presentations and updates from leading industry experts.
AI in drug discovery is leading the way into a shorter, cheaper and more successful R&D era where compound generation is automated, drug synthesis is predictable and undruggable diseases are finally being targeted.
AI in drug discovery is becoming an integral part of the research and development area of treating diseases with more companies incorporating ‘Big Data’ and data scientists within their R&D teams. Although the AI in drug discovery area has grown rapidly over the past few years, those in the industry acknowledge that there is a long way to go. Collaboration and partnerships are the key to driving this area forward.
Join us at SMi’s 3rd annual AI in Drug Discovery conference and explore the latest industry updates in: the selection of targets using AI, decision making within drug discovery and closing the loop on AI in drug discovery. Don’t miss out on presentations from leaders within the field, giving insights into the latest industry advances and answering the big questions within AI in Drug Discovery.
Event Hashtag: #SMiAIDrugDis
Key Reasons to Attend:

Discover the main topics of research within industry, with talks on decision making, target selection and closing the loop
Engage with regulators about the guidance within machine learning and AI in Drug Discovery
Learn about the new breakthroughs within clinical trials and the treatment of disease
Explore the latest technologies in deep learning from leaders within the pharmaceutical industry
Discuss the impact of big data and how it applies to AI drug discovery within Pharma

Who Should Attend?
CEOs, Presidents, Vice Presidents and Global Heads, Executive Directors, Vice President & Global head, Principal Scientists, Heads of Business Development, Directors of Pharma/Biotech firms.

Transcription Factor-Directed Therapies Summit
2022-03-08 - 2022-03-10 | Hyatt Regency Boston, One Ave. de Lafayette, Boston, MA, 02111, United States
The FDA’s recent approval of Welireg has sparked reinvigorated confidence in the field of Transcription Factor-therapeutics and as an increasing number of drug candidates are entering preclinical and clinical programs, this is a vital moment for the field.
For the first time, you can join leaders from BMS, Scorpion Therapeutics, Ikena Oncology, Kronos Bio and Talus Bio at the inaugural Transcription Factor-Directed Therapies Summit, the first in-person conference on precision molecular oncology uniting experts in proteomics, genomics, structural biology, and translational sciences.
Dedicated to overcoming specific drug development challenges of targeting this ubiquitous and highly complex system with novel TPD based modalities, this unique discussion forum will equip you with the knowledge to utilize Transcription Factors as biomarkers to better predict disease prognosis and progression.
Don’t miss your chance to join fellow pioneers of Transcription Factor medicine to overcome the critical roadblocks to success in small molecule inhibitors, PROTAC-based degraders, and other therapeutic approaches targeting STAT3, c-MYC, FOXP3, p53, MITF, NF-B, and many more Transcription Factors.
Ensure your Transcription Factor program reaches full clinical potential by gaining a better understanding of the underpinning biology of the transcription regulation network and how it relates to treating disease, whilst harnessing the novel discovery and screening technologies that are streamlining drug development and opening the field up to new therapeutics possibilities. Join us to seek out solutions to longstanding obstacles in transcription factor therapy development at all stages, from bench to bedside.
To know more visit: https://bit.ly/3pWWEj8

4th Chronic Kidney Disease Drug Development Summit
2022-03-01 - 2022-03-03 | Hyatt Regency Boston, One Ave. de Lafayette, Boston, MA, 02111, United States
As SGLT2 inhibitors redefine standard of care, opportunities to establish efficacy with surrogate endpoints take a step forward, and molecular phenotyping of disease etiology enables reclassification of patients to clinically actionable subtypes; drug development for chronic kidney disease has never been more exciting.
The 4th Chronic Kidney Disease Drug Development Summit is your only industry-led event dedicated to accelerating the frontier of preventative and regenerative therapies to meaningfully target kidney disease and enlighten opportunities for indication expansion into rare renal disorders. Uniting 100+ industry heavyweights including AstraZeneca, Johnson & Johnson, Bayer, Boehringer Ingelheim, Novartis, Otsuka, Novo Nordisk, and many more, this is a conversation you cannot afford to miss.
From dissecting pivotal insight into implementing patient stratification to turn the tide on precision medicine, to the brand-new seminar dedicated to establishing a pathway to clinical success in AKI, this is the only end-to-end forum presenting scientific advancements as actionable insights.
We hope to see you in Boston this March to together discover opportunities to personalize organ-on-a-chip technology and explore advances in stem cell platforms to regenerate kidney tissue. Leave this meeting equipped to guide your strategic decisions for 2022 and implement evolving surrogate endpoints of eGFR slope, albuminuria, and real-world evidence into innovative trial design.
Take a look at the event guide here.
